The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Open accessAbstract
Purpose: The 21-gene OncotypeDX recurrence score (RS) assay quantifies the risk of distant recurrence in tamoxifen-treated patients with node-negative, estrogen receptor (ER)–positive breast cancer. We investigated the association between RS and risk for locoregional recurrence (LRR) in patients with node-negative, ER-positive breast cancer from two National Surgical Adjuvant Breast and Bowel Project (NSABP) trials (NSABP B-14 and B-20). Patients and Methods: RS was available for 895 tamoxifen-treated patients (from both trials), 355 placebo-treated patients (from B-14), and 424 chemotherapy plus tamoxifen-treated patients (from B-20). The primary end point was time to first LRR. Distant metastases, second primary cancers, and deaths before LRR were censored. Results: In tamoxifen-treated patients, LRR was significantly associated with RS risk groups (P < .001). The 10-year Kaplan-Meier estimate of LRR was 4.% (95% CI, 2.3% to 6.3%) for patients with a low RS (< 18), 7.2% (95% CI, 3.4% to 11.0%) for those with intermediate RS (18-30), and 15.8% (95% CI, 10.4% to 21.2%) for those with a high RS (> 30). There were also significant associations between RS and LRR in placebo-treated patients from B-14 (P = .022) and in chemotherapy plus tamoxifen–treated patients from B-20 (P = .028). In multivariate analysis, RS was an independent significant predictor of LRR along with age and type of initial treatment. Conclusion: Similar to the association between RS and risk for distant recurrence, a significant association exists between RS and risk for LRR. This information has biologic consequences and potential clinical implications relative to locoregional therapy decisions for patients with node-negative and ER-positive breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Self-citationPaik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Self-citationHarris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Self-citationFisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.684 · Cited by 635
Self-citationMeasurement of Gene Expression in Archival Paraffin-Embedded Tissues
Cronin, M., Pho, M., Dutta, D., Stephans, J. C., Shak, S., Kiefer, M. C., Esteban, J. M., & Baker, J. B. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63093-3 · Cited by 551
Self-citationTamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
Fisher, B., Dignam, J., Emir, B., Bryant, J., DeCillis, A., Wolmark, N., Wickerham, D. L., Dimitrov, N. V., Abramson, N., Atkins, J. N., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1673 · Cited by 521
Self-citationHabel, L. A., Shak, S., Jacobs, M. K., Capra, A., Alexander, C., Pho, M., Baker, J., Walker, M., Watson, D., Hackett, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1412 · Cited by 484
Self-citationWapnir, I. L., Anderson, S. J., Mamounas, E. P., Geyer, C. E., Jeong, J.-H., Tan-Chiu, E., Fisher, B., & Wolmark, N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3273 · Cited by 466
Self-citationFoekens, J. A., Atkins, D., Zhang, Y., Sweep, F. C. G. J., Harbeck, N., Paradiso, A., Cufer, T., Sieuwerts, A. M., Talantov, D., Span, P. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9115 · Cited by 361
Fisher, B., Jeong, J.-H., Bryant, J., Anderson, S., Dignam, J., Fisher, E. R., & Wolmark, N. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16981-x · Cited by 359
Self-citationPredicting a local recurrence after breast-conserving therapy by gene expression profiling
Nuyten, D. S., Kreike, B., Hart, A. A., Chi, J.-T. A., Sneddon, J. B., Wessels, L. F., Peterse, H. J., Bartelink, H., Brown, P. O., Chang, H. Y., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1614 · Cited by 202
Cited by
Regional Nodal Irradiation in Early-Stage Breast Cancer
Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., Vallis, K. A., White, J. R., Rousseau, P., Fortin, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415340 · Cited by 1,294
Nguyen, P. L., Taghian, A. G., Katz, M. S., Niemierko, A., Abi Raad, R. F., Boon, W. L., Bellon, J. R., Wong, J. S., Smith, B. L., & Harris, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4287 · Cited by 811
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0021 · Cited by 806
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0035 · Cited by 664
Litière, S., Werutsky, G., Fentiman, I. S., Rutgers, E., Christiaens, M.-R., Van Limbergen, E., Baaijens, M. H., Bogaerts, J., & Bartelink, H. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70042-6 · Cited by 551
Metadata
- Authors
- Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., Watson, D., Geyer, C. E., Wickerham, D. L., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-01
- Volume
- 28
- Issue
- 10
- Pages
- 1677-1683
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133264822
- Cited by
- 619
- References
- 15
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.